Advanced Accelerator Applications SA
http://www.adacap.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Advanced Accelerator Applications SA
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.
Why Novartis Rejected Access Consortium In Favor Of Direct UK Radioligand Filing
A direct marketing authorization application to the UK medicines regulator offered a quicker route to approval for Novartis’ prostate cancer treatment Pluvicto than following the international Access Consortium process, because of the novel nature of the therapy, according to the company.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch
"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
-
- BioSynthema, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice